| Tota   | al No.                             | of pr | inted pages = 3                                       |                            |  |  |  |  |  |
|--|------------------------------------|-------|---|----------------------------|--|--|--|--|--|
| PY 132705  |                                    |       |   |                            |  |  |  |  |  |
| Roll No. of candidate  |                                    |       |   |                            |  |  |  |  |  |
| 2023   |                                    |       |   |                            |  |  |  |  |  |
| B.Pharm. 7th Semester (Old) End-Term (Repeater) Examination      |                                    |       |   |                            |  |  |  |  |  |
| PHARMACEUTICAL CHEMISTRY - VII (MED. CHEM-III)                   |                                    |       |   |                            |  |  |  |  |  |
| Ful  | Full Marks – 100 Time – Three hour |       |   |                            |  |  |  |  |  |
| -  |                                    |       |   | <del>*************</del> * |  |  |  |  |  |
| The figures in the margin indicate full marks for the questions. |                                    |       |   |                            |  |  |  |  |  |
| Answer question no. 1 and any six from the followings            |                                    |       |   |                            |  |  |  |  |  |
| 1.   | Mul                                | tiple | Choice Questions                                      | $(10 \times 1 = 10)$       |  |  |  |  |  |
|  | (i)                                | Whi   | ch of the following will be a pharmaceutical applica  | ation of prodrugs?         |  |  |  |  |  |
|  |                                    | (a)   | Enhancement of bioavailability                        |                            |  |  |  |  |  |
|  |                                    | (b)   | Reduction of toxicity                                 |                            |  |  |  |  |  |
|  |                                    | (c)   | Improvement of odour                                  |                            |  |  |  |  |  |
| 6  |                                    | (d)   | Site-specific drug delivery?                          |                            |  |  |  |  |  |
|  | (ii)                               | Why   | y carbenicillin cannot be given orally?               |                            |  |  |  |  |  |
|  |                                    | (a)   | Tastes bad  |                            |  |  |  |  |  |
|  |                                    | (b)   | Bad odour   |                            |  |  |  |  |  |
|  |                                    | (c)   | Degraded by saliva                                    |                            |  |  |  |  |  |
|  |                                    | (d)   | Hydrolysed easily.                                    |                            |  |  |  |  |  |
|  | (iii)                              | How   | y to prevent henetic first-ness metabolism for cortic | enstaroids?                |  |  |  |  |  |

(a) Providing intravenously

- (b) Providing orally
- (c) Form esters and ether products
- (d) By enhancing lipophilicity

|           | (iv)   | Whi   | ch is the earliest discovered prodrug?              |  |  |  |  |
|-----------|--------|---|---|--|--|--|--|
|           |        | (a)   | Prontosil   |  |  |  |  |
|           |        | (b)   | Sulphanilamide                                      |  |  |  |  |
|           |        | (c)   | Aspirin   |  |  |  |  |
|           |        | (d)   | Salicylic acid                                      |  |  |  |  |
|           | (v)    | Foll  | owing are the Phase I reactions except ————         |  |  |  |  |
|           |        | (a)   | Oxidative reactions                                 |  |  |  |  |
|           |        | (b)   | Hydrolytic reactions                                |  |  |  |  |
|           |        | (c)   | Reductive reactions                                 |  |  |  |  |
|           |        | (d)   | Sulphide reactions                                  |  |  |  |  |
|           | (vi)   | Which of the following does not affect the activity of penicillin?          |   |  |  |  |  |
|           |        | (a)   | bile  |  |  |  |  |
|           |        | (b)   | hydrochloric acid                                   |  |  |  |  |
|           |        | (c)   | cysteine  |  |  |  |  |
|           | -      | (d)   | sodium hydroxide                                    |  |  |  |  |
|           | (vii)  | Ant   | ibiotic produced by Streptomyces rimosus is         |  |  |  |  |
|           |        | (a)   | chlortetracycline                                   |  |  |  |  |
|           |        | (b)   | oxytetracycline                                     |  |  |  |  |
|           |        | (c)   | tetracycline  |  |  |  |  |
|           |        | (d)   | doxycycline   |  |  |  |  |
|           | (viii) | viii) Acycloguanosine is a nucleoside analogue which is active against ———— |   |  |  |  |  |
|           |        | (a)   | Influenza A virus                                   |  |  |  |  |
|           | 20     | (b)   | HIV virus   |  |  |  |  |
|           |        | (c)   | Herpes virus  |  |  |  |  |
|           |        | (d)   | Influenza B virus                                   |  |  |  |  |
|           | (ix)   | Whi   | Which antineoplastic drug is a folic acid analogue? |  |  |  |  |
|           |        | (a)   | Methotrexate  |  |  |  |  |
|           |        | (b)_  | Mercaptopurine                                      |  |  |  |  |
|           |        | (c)   | Cytarabine  |  |  |  |  |
|           |        | (d)   | Fluorouracil  |  |  |  |  |
| PY 132705 |        | 5   | 2   |  |  |  |  |

|    | (x) | Peptide bond is ————   |                    |  |  |
|----|-----|--|--------------------|--|--|
|    |     | (a) Covalent bond  |                    |  |  |
|    |     | (b) Ionic bond   |                    |  |  |
|    |     | (c) Metallic bond  |                    |  |  |
|    |     | (d) Hydrogen bond  |                    |  |  |
| 2. | (a) | What are pro drugs? How are they different from other medications? (2+3=5) |                    |  |  |
|    | (b) | Why are prodrug used and how do they work? Explain it example.             | with suitable      |  |  |
|    |     |  | (5+5=10)           |  |  |
| 3. | (a) | Explain the term Drug metabolism.  | (2)                |  |  |
|    | (b) | Describe Phase-I and Phase-II drug metabolism elaborately.                 | (6+7=13)           |  |  |
| 4. | (a) | Classify antineoplastic drugs with one example each.                       | (6)                |  |  |
|    | (b) | Describe the synthesis of the following drugs:                             | $(3 \times 3 = 9)$ |  |  |
|    |     | (i) Chlorambucil   |                    |  |  |
|    |     | (ii) Methotrexate  |                    |  |  |
|    |     | (iii) Thiotepa   |                    |  |  |
| 5. | (a) | Explain the structure activity relationship of Tetracyclines.              | (10)               |  |  |
|    | (b) | Describe the synthesis and uses of Dapsone and Isoniazid.                  | (2.5+2.5=5)        |  |  |
| 6. | (a) | Describe immunosuppressive and immunostimulants citing ex                  | ample. (10)        |  |  |
|    | (b) | Explain Anthelmintics with node of action and uses.                        | (5)                |  |  |
| 7. | (a) | Classify penicillin with proper example and structure.                     | (10)               |  |  |
|    | (b) | Describe the synthesis of Ciprofloxacin and Nalidixic acid.                | (2.5+2.5=5)        |  |  |
| 8. | (a) | Explain Antiseptic and disinfection with proper example.                   | (5+5=10)           |  |  |
|    | (b) | Explain the synthesis of two antifungal drugs.                             | (2+5+2.5=5)        |  |  |
| 9. | (a) | Explain thyroid and antithyroid drugs citing example.                      | (6)                |  |  |
|    | (b) | Write down the synthesis of Amantedine, Acyclovir and Zidovi               | idine.             |  |  |
|    |     |  | (3+3+3=9)          |  |  |